JP2017517520A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017517520A5 JP2017517520A5 JP2016569847A JP2016569847A JP2017517520A5 JP 2017517520 A5 JP2017517520 A5 JP 2017517520A5 JP 2016569847 A JP2016569847 A JP 2016569847A JP 2016569847 A JP2016569847 A JP 2016569847A JP 2017517520 A5 JP2017517520 A5 JP 2017517520A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- composition according
- patient
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462004298P | 2014-05-29 | 2014-05-29 | |
| US62/004,298 | 2014-05-29 | ||
| PCT/US2015/032351 WO2015183776A1 (en) | 2014-05-29 | 2015-05-26 | Methods for treating cancer with a wee1 inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019232432A Division JP2020073520A (ja) | 2014-05-29 | 2019-12-24 | Ｗｅｅ１阻害剤を用いた癌を処置する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017517520A JP2017517520A (ja) | 2017-06-29 |
| JP2017517520A5 true JP2017517520A5 (enExample) | 2018-06-28 |
Family
ID=54699632
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016569847A Pending JP2017517520A (ja) | 2014-05-29 | 2015-05-26 | Ｗｅｅ１阻害剤を用いた癌を処置する方法 |
| JP2019232432A Pending JP2020073520A (ja) | 2014-05-29 | 2019-12-24 | Ｗｅｅ１阻害剤を用いた癌を処置する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019232432A Pending JP2020073520A (ja) | 2014-05-29 | 2019-12-24 | Ｗｅｅ１阻害剤を用いた癌を処置する方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US20170095479A1 (enExample) |
| EP (1) | EP3148544A4 (enExample) |
| JP (2) | JP2017517520A (enExample) |
| WO (1) | WO2015183776A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015183776A1 (en) * | 2014-05-29 | 2015-12-03 | Merck Sharp & Dohme Corp. | Methods for treating cancer with a wee1 inhibitor |
| WO2019134070A1 (en) * | 2018-01-02 | 2019-07-11 | Rui Jin Hospital, Shanghai Jiao Tong University School Of Medicine | Panda as novel therapeutic |
| IL283639B2 (en) | 2018-12-20 | 2024-06-01 | Amgen Inc | Kif18a inhibitors |
| CA3165472A1 (en) * | 2019-12-20 | 2021-06-24 | Recurium Ip Holdings, Llc | Combinations |
| JP2023521802A (ja) * | 2020-04-14 | 2023-05-25 | アムジエン・インコーポレーテツド | 新生物疾患の処置のためのｋｉｆ１８ａ阻害剤 |
| AU2021290701A1 (en) * | 2020-06-17 | 2023-02-02 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | Pyrazolo(3,4-d)pyrimidine-3-ketone derivative as Wee-1 inhibitor |
| CN116249689A (zh) * | 2020-06-24 | 2023-06-09 | 皮姆维制药公司 | 用于再激活突变p53的化合物的伴随诊断工具 |
| KR20240109977A (ko) | 2021-08-26 | 2024-07-12 | 볼라스트라 쎄라퓨틱스, 인코포레이티드 | Kif18a의 스피로 인돌린 억제제 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2168966T3 (pl) * | 2007-06-15 | 2017-06-30 | Msd K.K. | Pochodna bicykloaniliny |
| WO2011027800A1 (en) * | 2009-09-02 | 2011-03-10 | Banyu Pharmaceutical Co.,Ltd. | Use of biomarker(s) to identify a wee1 inhibitor responsive patient and methods of treating cancer mediated by dysfunctional or aberrant p53 via administration of a wee1 inhibitor |
| CN108721284A (zh) * | 2010-11-16 | 2018-11-02 | 阵列生物制药公司 | 检测点激酶1抑制剂和wee1激酶抑制剂的组合 |
| US9506926B2 (en) * | 2011-02-18 | 2016-11-29 | The Regents Of The University Of California | Molecular predictors of therapeutic response to specific anti-cancer agents |
| US9345705B2 (en) * | 2011-09-15 | 2016-05-24 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
| WO2015183776A1 (en) * | 2014-05-29 | 2015-12-03 | Merck Sharp & Dohme Corp. | Methods for treating cancer with a wee1 inhibitor |
-
2015
- 2015-05-26 WO PCT/US2015/032351 patent/WO2015183776A1/en not_active Ceased
- 2015-05-26 JP JP2016569847A patent/JP2017517520A/ja active Pending
- 2015-05-26 US US15/314,650 patent/US20170095479A1/en not_active Abandoned
- 2015-05-26 EP EP15800163.6A patent/EP3148544A4/en not_active Ceased
-
2019
- 2019-12-06 US US16/705,592 patent/US11364243B2/en active Active
- 2019-12-24 JP JP2019232432A patent/JP2020073520A/ja active Pending
-
2022
- 2022-05-23 US US17/664,476 patent/US20230083689A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016525097A5 (enExample) | ||
| JP2021521194A5 (enExample) | ||
| PE20170312A1 (es) | Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso | |
| JP2021526132A5 (enExample) | ||
| JP2015533176A5 (enExample) | ||
| JP2016533366A5 (enExample) | ||
| MX384828B (es) | Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso. | |
| FI3618875T3 (fi) | Raf-inhibiittoria ja trametinibia käsittävä yhdistelmähoito | |
| JP2018507249A5 (enExample) | ||
| NZ602385A (en) | Methods of treating cancer | |
| PH12015502046A1 (en) | Pyridinyl and fused pyridinyl triazolone derivatives | |
| PH12016502354A1 (en) | Pharmaceutical composition | |
| MX2015011752A (es) | Metodos para tratar cancer de pulmon. | |
| JP2015536950A5 (enExample) | ||
| NZ732154A (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
| JP2017528475A5 (enExample) | ||
| WO2014180889A8 (en) | Methods and compositions for the treatment of cancer | |
| PH12016502249A1 (en) | Pladienolide pyridine compounds and methods of use | |
| JP2015512398A5 (enExample) | ||
| JP2017527582A5 (enExample) | ||
| WO2013112950A3 (en) | Certain chemical entities, compositions, and methods | |
| MX2016000131A (es) | Nanoparticulas polimericas de docetaxel para el tratamiento de cancer. | |
| JP2017535601A5 (enExample) | ||
| WO2016127168A3 (en) | Mebendazole polymorph for treatment and prevention of tumors | |
| EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения |